Glenmark Pharmaceuticals Limited (NSE: GLENMARK, BSE: 532296) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹75,556 Cr, it ranks #148 by market cap among the 6,197 Indian listed companies on FinBizNet, and #9 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,640.00 (as of 16 Nov 2026), the share price is 2.7% below its 52-week high of ₹2,714.00 and 45.9% above its 52-week low of ₹1,810.00. The share price is up 45.7% over one year and up 13.8% over three months.
| Current Price | ₹2,640.00 |
|---|---|
| Market Cap | ₹75,556 Cr |
| NSE Symbol | GLENMARK |
| BSE Code | 532296 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 55.1 |
| Return on Equity | 14.07% |
| Return on Assets | 14.11% |
| 52-Week Range | ₹1,810.00 – ₹2,714.00 |
| 1-Year Price Change | +45.7% |
| 3-Month Price Change | +13.8% |
| Beta (1Y) | 0.23 |
| Dividend Yield | 0.19% |
| Headquarters | Mumbai, Maharashtra |
| Website | glenmarkpharma.com |
| Revenue | ₹4,157 Cr |
|---|---|
| Net Profit | ₹264 Cr |
| Net Margin | 6.3% |
| EPS (Basic) | ₹9.35 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Glenmark Pharmaceuticals Limited reported revenue of ₹4,157 Cr in Q2 FY27, down 31.3% from ₹6,047 Cr in Q2 FY26 and up 3.4% from ₹4,018 Cr in Q1 FY27. It posted a net profit of ₹264 Cr for the quarter, against a net profit of ₹610 Cr in Q2 FY26 (down 56.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹3,256 Cr (Q4 FY25) to ₹6,047 Cr (Q2 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹4,157 Cr | ₹264 Cr | 6.3% |
| Q1 FY27 | ₹4,018 Cr | ₹483 Cr | 12.0% |
| Q4 FY26 | ₹3,771 Cr | ₹301 Cr | 8.0% |
| Q3 FY26 | ₹3,901 Cr | ₹403 Cr | 10.3% |
| Q2 FY26 | ₹6,047 Cr | ₹610 Cr | 10.1% |
| Q1 FY26 | ₹3,264 Cr | ₹47 Cr | 1.4% |
| Q4 FY25 | ₹3,256 Cr | ₹4 Cr | 0.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 46.65% of Glenmark Pharmaceuticals Limited's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 45.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for
1. Pharmaceuticals-This segment develops, manufactures, and markets pharmaceutical products. It provides active pharmaceutical ingredients in the therapeutic areas of alimentary track, anti-infective, anti-parasitic, cardiovascular, central nervous system, dermatological, genito-urinary, musculo-skeletal, respiratory, and others; and formulations in the therapeutic areas of dermatology, respiratory, cardiovascular, anti- diabetic, and oncology.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Glenmark Pharmaceuticals Limited | ₹75,556 Cr | 55.1 | 14.07% | ₹4,157 Cr | +45.7% |
Listed by market capitalisation. Ratios are shown for context only.
Glenmark Pharmaceuticals Limited is trading at ₹2,640.00, with a market capitalisation of ₹75,556 Cr.
Glenmark Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Glenmark Pharmaceuticals Limited has a P/E of 55.1 and a return on equity of 14.07%.
Glenmark Pharmaceuticals Limited is listed on the NSE under the symbol GLENMARK and on the BSE under the scrip code 532296.
Glenmark Pharmaceuticals Limited's share price is up 45.7% over one year and up 13.8% over three months. Its 52-week range is ₹1,810.00 to ₹2,714.00.
In Q2 FY27, Glenmark Pharmaceuticals Limited reported revenue of ₹4,157 Cr and net profit of ₹264 Cr, with basic EPS of ₹9.35 (consolidated, parsed from the company's exchange filing).
Glenmark Pharmaceuticals Limited reported revenue of ₹4,157 Cr in Q2 FY27, down 31.3% from ₹6,047 Cr in Q2 FY26 and up 3.4% from ₹4,018 Cr in Q1 FY27.
Promoters held 46.65% of Glenmark Pharmaceuticals Limited's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.